Literature DB >> 19274046

Tenofovir renal toxicity targets mitochondria of renal proximal tubules.

James J Kohler1, Seyed H Hosseini, Amy Hoying-Brandt, Elgin Green, David M Johnson, Rodney Russ, Dung Tran, C Michael Raper, Robert Santoianni, William Lewis.   

Abstract

Tenofovir disoproxil fumarate (TDF) is an analog of adenosine monophosphate that inhibits HIV reverse transcriptase in HIV/AIDS. Despite its therapeutic success, renal tubular side effects are reported. The mechanisms and targets of tenofovir toxicity were determined using '2 x 2' factorial protocols, and HIV transgenic (TG) and wild-type (WT) littermate mice with or without TDF (5 weeks). A parallel study used didanosine (ddI) instead of TDF. At termination, heart, kidney, and liver samples were retrieved. Mitochondrial DNA (mtDNA) abundance, and histo- and ultrastructural pathology were analyzed. Laser-capture microdissection (LCM) was used to isolate renal proximal tubules for molecular analyses. Tenofovir increased mtDNA abundance in TG whole kidneys, but not in their hearts or livers. In contrast, ddI decreased mtDNA abundance in the livers of WTs and TGs, but had no effect on their hearts or kidneys. Histological analyses of kidneys showed no disruption of glomeruli or proximal tubules with TDF or ddI treatments. Ultrastructural changes in renal proximal tubules from TDF-treated TGs included an increased number and irregular shape of mitochondria with sparse fragmented cristae. LCM-captured renal proximal tubules from TGs showed decreased mtDNA abundance with tenofovir. The results indicate that tenofovir targets mitochondrial toxicity on the renal proximal tubule in an AIDS model.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19274046      PMCID: PMC2674517          DOI: 10.1038/labinvest.2009.14

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  36 in total

Review 1.  Mitochondrial dna depletion, oxidative stress, and mutation: mechanisms of dysfunction from nucleoside reverse transcriptase inhibitors.

Authors:  W Lewis; W C Copeland; B J Day
Journal:  Lab Invest       Date:  2001-06       Impact factor: 5.662

2.  In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells.

Authors:  Francesc Vidal; Joan Carles Domingo; Jordi Guallar; Maria Saumoy; Begoña Cordobilla; Rainel Sánchez de la Rosa; Marta Giralt; Maria Luisa Alvarez; Miguel López-Dupla; Ferran Torres; Francesc Villarroya; Tomas Cihlar; Pere Domingo
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

3.  Cardiac dysfunction occurs in the HIV-1 transgenic mouse treated with zidovudine.

Authors:  W Lewis; I L Grupp; G Grupp; B Hoit; R Morris; A M Samarel; L Bruggeman; P Klotman
Journal:  Lab Invest       Date:  2000-02       Impact factor: 5.662

4.  Targeted transgenic overexpression of mitochondrial thymidine kinase (TK2) alters mitochondrial DNA (mtDNA) and mitochondrial polypeptide abundance: transgenic TK2, mtDNA, and antiretrovirals.

Authors:  Seyed H Hosseini; James J Kohler; Chad P Haase; Nina Tioleco; Tami Stuart; Erin Keebaugh; Tomika Ludaway; Rodney Russ; Elgin Green; Robert Long; Liya Wang; Staffan Eriksson; William Lewis
Journal:  Am J Pathol       Date:  2007-03       Impact factor: 4.307

5.  Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice.

Authors:  W Lewis; C P Haase; S M Raidel; R B Russ; R L Sutliff; B D Hoit; A M Samarel
Journal:  Lab Invest       Date:  2001-11       Impact factor: 5.662

6.  Absence of a universal mechanism of mitochondrial toxicity by nucleoside analogs.

Authors:  Kaleb C Lund; LaRae L Peterson; Kendall B Wallace
Journal:  Antimicrob Agents Chemother       Date:  2007-04-30       Impact factor: 5.191

7.  Cardiac-targeted transgenic mutant mitochondrial enzymes: mtDNA defects, antiretroviral toxicity and cardiomyopathy.

Authors:  James J Kohler; Seyed H Hosseini; Elgin Green; Amy Hoying-Brandt; Ioan Cucoranu; Chad P Haase; Rodney Russ; Jaya Srivastava; Kristopher Ivey; Tomika Ludaway; Victor Kapoor; Allison Abuin; Alexsey Shapoval; Robert Santoianni; Ann Saada; Orly Elpeleg; William Lewis
Journal:  Cardiovasc Toxicol       Date:  2008-04-30       Impact factor: 3.231

8.  Effect of tenofovir on renal glomerular and tubular function.

Authors:  Christoph A Fux; Anna Christen; Susanne Zgraggen; Markus G Mohaupt; Hansjakob Furrer
Journal:  AIDS       Date:  2007-07-11       Impact factor: 4.177

9.  HIV-associated nephropathy.

Authors:  Christina M Wyatt; Paul E Rosenstiel; Paul E Klotman
Journal:  Contrib Nephrol       Date:  2008       Impact factor: 1.580

10.  Chronic renal failure among HIV-1-infected patients.

Authors:  Amanda Mocroft; Ole Kirk; Jose Gatell; Peter Reiss; Panagiotis Gargalianos; Kai Zilmer; Marek Beniowski; Jean-Paul Viard; Schlomo Staszewski; Jens D Lundgren
Journal:  AIDS       Date:  2007-05-31       Impact factor: 4.177

View more
  66 in total

Review 1.  The role of transporters in the toxicity of nucleoside and nucleotide analogs.

Authors:  Christopher A Koczor; Rebecca A Torres; William Lewis
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-04-18       Impact factor: 4.481

2.  Adverse outcome pathway for aminoglycoside ototoxicity in drug-resistant tuberculosis treatment.

Authors:  Hyejeong Hong; Kelly E Dooley; Laura E Starbird; Howard W Francis; Jason E Farley
Journal:  Arch Toxicol       Date:  2019-04-08       Impact factor: 5.153

3.  Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B.

Authors:  Andrés Duarte-Rojo; E Jenny Heathcote
Journal:  Therap Adv Gastroenterol       Date:  2010-03       Impact factor: 4.409

4.  Association of tenofovir exposure with kidney disease risk in HIV infection.

Authors:  Rebecca Scherzer; Michelle Estrella; Yongmei Li; Andy I Choi; Steven G Deeks; Carl Grunfeld; Michael G Shlipak
Journal:  AIDS       Date:  2012-04-24       Impact factor: 4.177

Review 5.  Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention.

Authors:  Atefeh Jafari; Hossein Khalili; Simin Dashti-Khavidaki
Journal:  Eur J Clin Pharmacol       Date:  2014-06-25       Impact factor: 2.953

Review 6.  Update on tenofovir toxicity in the kidney.

Authors:  Andrew M Hall
Journal:  Pediatr Nephrol       Date:  2012-08-10       Impact factor: 3.714

7.  Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults.

Authors:  Gautam Baheti; Jennifer R King; Edward P Acosta; Courtney V Fletcher
Journal:  AIDS       Date:  2013-01-14       Impact factor: 4.177

Review 8.  Urinary biomarkers of kidney diseases in HIV-infected children.

Authors:  Sofia Perazzo; Ángel A Soler-García; Yetrib Hathout; Jharna R Das; Patricio E Ray
Journal:  Proteomics Clin Appl       Date:  2015-06       Impact factor: 3.494

9.  The Use of Cytochrome C Oxidase Enzyme Activity and Immunohistochemistry in Defining Mitochondrial Injury in Kidney Disease.

Authors:  Zsuzsanna K Zsengellér; Seymour Rosen
Journal:  J Histochem Cytochem       Date:  2016-09       Impact factor: 2.479

10.  Tenofovir-associated bone density loss.

Authors:  Iwen F Grigsby; Lan Pham; Louis M Mansky; Raj Gopalakrishnan; Kim C Mansky
Journal:  Ther Clin Risk Manag       Date:  2010-02-02       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.